Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 5 of 48 · 2295 articles
Synthetic, severity-controlled endoscopic images could help researchers train and test IBD imaging algorithms and augment scarce labeled datasets, which may accelerate development of tools that interpret endoscopy for...
This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety...
This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...
People with IBD (Crohn’s disease or ulcerative colitis) can develop vitamin K deficiency from malabsorption; this label clarifies that Vitamin K1 Injection is indicated for such situations and highlights important safety...
The FDA label defines who may be prescribed tofacitinib and highlights important safety warnings (serious infections, increased mortality signal, and malignancy risk) relevant to people with IBD and other autoimmune...
The review connects animal-model discoveries (IL-23/IL-17 and TNF pathways, gut–joint interactions) to therapies and research priorities relevant to people with SpA and IBD-associated arthritis.
Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.
Planned synthesis of global surgical rates and outcomes in the biologics era could help clinicians, patients, and researchers understand how often surgery is needed, what types of operations are performed, and common...
Preclinical research identified a plant-derived compound (polydatin) that may rebalance immune responses relevant to ulcerative colitis by targeting KEAP1–NFE2L2 signaling and reducing inflammatory T‑cell activity. This...
This study shows that people with IBD can display distinct self-care and illness-perception profiles rather than a single pattern; tailoring education and psychological support to these profiles could improve...
This work suggests a new way Crohn’s disease might begin: a weaker early immune response (linked to NOD2 gene defects) allows small intestinal infections to persist and later trigger the inflammation that causes...
Postoperative endoscopic recurrence after ileocolic resection is an important risk for people with Crohn’s disease; this study links HNBT and possibly e-cigarette use to higher recurrence rates, which could affect...
This affects Crohn’s disease research funding and future drug-development pathways: a major pharmaceutical partner ended a collaboration that had aimed to discover T‑cell targets for Crohn’s disease, which could slow or...
Timing of therapies and daily behaviors may affect drug metabolism, immune activity, and symptom patterns in IBD. Considering when treatments are given could potentially improve response, reduce toxicity, and help...
This Taiwanese multicenter real-world study reports high 52-week clinical response and remission rates, sustained one-year drug persistence, and meaningful fistula healing with ustekinumab in patients with Crohn’s...
People with IBD who need weight loss or have metabolic problems may encounter GLP-1 receptor agonists; this review suggests those drugs reduced weight and improved metabolic measures in people with IBD without clear...
Accurate measurement of physical activity matters because it’s linked to symptoms, fitness, and overall health.
The study describes a new ultrasound-activated nanozyme that reduced intestinal inflammation and promoted mucosal repair in preclinical IBD models by scavenging ROS and modulating the gut microbiota—an approach that...
Many women with UC use hormonal contraception and worry it might worsen disease activity. This study provides evidence that HCT was not linked to more recurrent flares or higher cumulative inflammatory burden in the...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Functional...
CAR-based cellular therapies could offer a new way to reset immune responses in some forms of IBD, potentially helping patients who do not respond to existing biologics or small molecules.
Individual factors like CYP2C9 genotype and liver impairment can raise etrasimod levels. The study’s model-based dose suggestions could help personalize dosing to reduce risk of excess exposure.
Cure8 could only read part of this source from hcplive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease and Medications.
A new Phase 3 trial is testing ponesimod, an oral S1P-modulator, for moderately to severely active ulcerative colitis — this could expand oral treatment options if later shown effective and safe.
This trial tests whether the common sweetener sucralose alters the gut microbiome in people with Crohn’s disease in remission compared with healthy volunteers.
Diagnosis between UC, Crohn’s disease, and unclassified IBD can change in a meaningful minority of patients over years. Awareness of common reasons for reclassification (segmental disease, strictures) helps guide...
Dietary patterns like the Mediterranean diet may reduce inflammation and improve quality of life for people with Crohn’s disease by beneficially altering the gut microbiome and inflammatory markers. That could offer a...
New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...
Mesalazine is commonly used in ulcerative colitis; recognizing rare but serious myocarditis linked to it can lead to rapid treatment changes and recovery. Distinguishing drug-induced myocarditis from IBD-related...
The study suggests a targeted microbiome-based drug (sialidase inhibitor) may protect the mucus barrier and improve symptoms in ulcerative colitis without the broad disruption caused by antibiotics, which could be...
Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...
The paper reports a materials-based strategy to improve zinc delivery and bioavailability that reduced dose while preserving beneficial effects in a mouse colitis model—relevant because zinc supports intestinal health...
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
The study tests whether fewer random biopsies are needed during surveillance colonoscopy with modern high-definition scopes — a question that could change how often biopsies are taken, affect procedure time, costs, and...
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Inflammopharmacology.
This preclinical study identifies Thymosin β4 as a protective factor in intestinal inflammation and fibrosis and suggests rhTβ4 could be explored as a new therapeutic approach for IBD by targeting mineralocorticoid...
This study suggests that an intermittent fasting pattern (alternate-day fasting) increased intestinal injury, reduced immune cells, and caused anemia in a mouse model of acute colitis, implying such diets might be risky...
Identifies specific gut bacteria and fecal bilirubin metabolites that may link microbial loss to increased oxidative burden in IBD; suggests new biomarker candidates and targets for functional follow-up.
People with UC who undergo IPAA may want to know which clinical factors raise the chance of developing chronic pouchitis so they and their clinicians can plan monitoring and care. The study identifies several patient-...
The paper reports a novel small molecule (CA-23) that directly antagonizes CD28, reducing pathogenic T cell responses in preclinical IBD models and in cells from IBD donors. If validated, this represents a...
The study identifies thymosin β4 as a protective factor in experimental colitis and suggests an injectable/oral recombinant peptide might reduce inflammation and intestinal fibrosis by suppressing mineralocorticoid...
Patients and clinicians interested in Crohn’s disease should note a new company (Fibrx) is prioritizing drugs that directly target fibrosis and strictures — an area with few medical options today.
If validated, blood-based AI predictors of organ-specific aging might help flag organs aging faster in people with Crohn’s disease or other conditions, potentially enabling earlier monitoring or research into causes....
Recognizing eye inflammation as a possible early sign of IBD could shorten diagnostic delays and lead to earlier gastroenterology evaluation and treatment, which is especially important for children who often wait years...
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
The study uses generative AI and microbiome/RNA data to search for biomarkers of intestinal fibrosis in Crohn’s disease, which could help spot scarring earlier and potentially prevent worsening complications like...
